The development of lipopeptides (lipidated peptides) for vaccines is discussed, including
their role as antigens and/or adjuvants. Distinct classes of lipopeptide architectures are …

Heterologous prime-boost COVID-19 vaccine strategy may facilitate mass COVID-19
immunization. We reported early immunogenicity and safety outcomes of heterologous …

Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy.
The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of …

Nonhuman primates are critically important animal models in which to study complex human
diseases, understand biological functions, and address the safety of new diagnostics and …

Transplant recipients were excluded from the initial clinical trials determining safety and
efficacy of the landmark COVID-19 vaccines. Further, there is increasing evidence that …

To prepare for future coronavirus (CoV) pandemics, it is desirable to generate vaccines
capable of eliciting broadly neutralizing antibody responses to CoVs. Here, we show that …

Epstein–Barr virus (EBV) is a human herpesvirus that is common among the global
population, causing an enormous disease burden. EBV can directly cause infectious …

We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to
immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum …

Abstract The Coronavirus disease 2019 (COVID-19) pandemic has affected more than 269
million worldwide, with more than five million deaths as of early December 2021. The main …

New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine
platform for preparedness against emerging viral pathogens. Applying platform optimization …